Therefore, our study aimed to show that a bispecific lectibody with the lectin Stx1B as tumor-targeting domain and scFv OKT3 as a T cell engager could redirect T lymphocytes’ cytotoxicity towards Gb3-expressing tumor cells. The gene discussed is STX1B; the disease is neoplasm.